Literature DB >> 18024411

Acquisition of loss of the wild-type NRAS locus with aggressive disease progression in a patient with juvenile myelomonocytic leukemia and a heterozygous NRAS mutation.

Kazuyuki Matsuda, Yozo Nakazawa, Kazuo Sakashita, Masaaki Shiohara, Kazuyoshi Yamauchi, Kenichi Koike.   

Abstract

In a patient with juvenile myelomonocytic leukemia, a NRAS mutation at codon 12 (GGT>TGT) was initially heterozygous, but became homozygous after blastic crisis (BC). According to microsatellite and FISH analyses, the post-BC homozygous mutation might result from the loss of the wild-type NRAS locus through mitotic recombination.

Entities:  

Mesh：

Year:  2007        PMID： 18024411     DOI： 10.3324/haematol.11503

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  6 in total

1.  Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia.

Authors:  K Matsuda; Y Nakazawa; C Iwashita; T Kurata; K Hirabayashi; S Saito; M Tanaka; K Yoshikawa; R Yanagisawa; K Sakashita; S Sasaki; T Honda; K Koike
Journal:  Leukemia       Date:  2014-02-05       Impact factor: 11.528

2.  Clinical course of juvenile myelomonocytic leukemia in the blast crisis phase treated by acute myeloid leukemia-oriented chemotherapy and allogeneic hematopoietic stem cell transplantation.

Authors:  Satoshi Ueda; Naoki Sakata; Hideki Muramatsu; Hirotoshi Sakaguchi; Xinan Wang; Yinyan Xu; Seiji Kojima; Toshihiro Yamaguchi; Takeshi Higa; Tsukasa Takemura
Journal:  Int J Hematol       Date:  2014-07-22       Impact factor: 2.490

Review 3.  RAS diseases in children.

Authors:  Charlotte M Niemeyer
Journal:  Haematologica       Date:  2014-11       Impact factor: 9.941

4.  Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.

Authors:  Jin Xu; Kevin M Haigis; Ari J Firestone; Megan E McNerney; Qing Li; Elizabeth Davis; Shann-Ching Chen; Joy Nakitandwe; James Downing; Tyler Jacks; Michelle M Le Beau; Kevin Shannon
Journal:  Cancer Discov       Date:  2013-06-03       Impact factor: 39.397

5.  Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.

Authors:  Aurélie Caye; Marion Strullu; Fabien Guidez; Bruno Cassinat; Steven Gazal; Odile Fenneteau; Elodie Lainey; Kazem Nouri; Saeideh Nakhaei-Rad; Radovan Dvorsky; Julie Lachenaud; Sabrina Pereira; Jocelyne Vivent; Emmanuelle Verger; Dominique Vidaud; Claire Galambrun; Capucine Picard; Arnaud Petit; Audrey Contet; Marilyne Poirée; Nicolas Sirvent; Françoise Méchinaud; Dalila Adjaoud; Catherine Paillard; Brigitte Nelken; Yves Reguerre; Yves Bertrand; Dieter Häussinger; Jean-Hugues Dalle; Mohammad Reza Ahmadian; André Baruchel; Christine Chomienne; Hélène Cavé
Journal:  Nat Genet       Date:  2015-10-12       Impact factor: 38.330

Review 6.  Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia.

Authors:  Claudia Fiñana; Noel Gómez-Molina; Sandra Alonso-Moreno; Laura Belver
Journal:  Cancers (Basel)       Date:  2022-03-04       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.